United States — Food and Drug Administration & Paragon Therapeutics
8 shared events · Importance 4 · Last updated Sep 19, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee is convening a meeting to review Paragon Therapeutics' Biologics License Application for Deramiocel, which is a critical step in the regulatory approval process for the drug.
Paragon Therapeutics: Paragon Therapeutics announced that the Cellular, Tissue, and Gene Therapies Advisory Committee of the United States — Food and Drug Administration will convene a meeting to discuss its Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy. This is a significant step towards potential market approval for their lead product candidate.
Jun 26, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: Regulator whose briefing documents and advisory committee vote triggered the stock collapse and legal actions.
Paragon Therapeutics: Central company facing regulatory rejection and multiple securities fraud lawsuits; stock collapsed over 78%.
Jul 27, 2026 · 305 articles
Regulatory
United States — Food and Drug Administration: The FDA's July 27, 2026 briefing documents and July 29 advisory committee meeting triggered the stock collapse underlying the lawsuit, and its extension of the Deramiocel PDUFA date to November 22, 2026 keeps the review active.
Paragon Therapeutics: Capricor is the central defendant in the securities fraud class action and the issuer whose Deramiocel BLA and statistical analysis plan changes are at the heart of the dispute. The litigation, the 64% stock drop, and the extended PDUFA date to November 22, 2026 leave its equity under heavy pressure and its regulatory path uncertain.
Aug 10, 2026 · 267 articles
Regulatory
United States — Food and Drug Administration: The FDA is mentioned as the regulatory body that had not agreed to Capricor's statistical analysis plan changes, which is central to the allegations. The agency's actions or lack thereof are key to the lawsuit's claims.
Paragon Therapeutics: Capricor is the defendant in the securities class action, facing allegations of misleading investors regarding its Deramiocel BLA and statistical analysis plan changes. The lawsuit and upcoming lead plaintiff deadline could negatively affect its stock price and reputation.
Sep 21, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The FDA is reviewing the U.S. NDA for NCX 470, with approval expected in summer 2027. Its decision is critical for the drug's launch in the U.S.
Paragon Therapeutics: Ocumension is the exclusive licensee in China and submitted the NDA. It has already invested €18 million in license fees and contributed to trial costs, positioning itself for a commercial launch and potential revenue from NCX 470 sales.
Aug 10, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The FDA is the subject of the restructuring, which could reshape its leadership and regulatory approach, affecting drug approvals and AI oversight.
Paragon Therapeutics: Capricor received a review extension for its Duchenne muscular dystrophy drug after an adverse advisory committee vote, adding uncertainty.
Aug 25, 2026 · 6 articles
Business
United States — Food and Drug Administration: Approved Phase 2 trial protocol for MTX652.
Paragon Therapeutics: Divests MTX652 to focus on CNS pipeline, receives up to $292M in payments.
Jul 17, 2026 · 6 articles
Business
Paragon Therapeutics: Paragon Therapeutics, NicOx's exclusive licensee in China, received positive pre-submission regulatory feedback for NCX 470, allowing them to proceed with the New Drug Application submission in China. This is a significant step towards commercializing the drug in their licensed territories.
Jun 18, 2026 · 7 articles
100
United States — Food and Drug Administration published briefing documents Paragon TherapeuticsCapricor Deramiocel...
99
United States — Food and Drug Administration denied Biologics License Application Paragon TherapeuticsCapricor Deramiocel...
99
United States — Food and Drug Administration released briefing documents Paragon TherapeuticsCapricor Deramiocel...
99
Paragon Therapeutics announced advisory meeting United States — Food and Drug AdministrationCapricor Deramiocel...
96
United States — Food and Drug Administration released briefing documents Paragon TherapeuticsCapricor Deramiocel...
93
United States — Food and Drug Administration released briefing documents Paragon TherapeuticsCapricor Deramiocel...
92
United States — Food and Drug Administration published briefing documents Paragon TherapeuticsCapricor Deramiocel...
90
United States — Food and Drug Administration issued Complete Response Letter Paragon TherapeuticsCapricor Deramiocel...
90
United States — Food and Drug Administration published briefing documents Paragon TherapeuticsCapricor Deramiocel...
87
United States — Food and Drug Administration held advisory committee Paragon TherapeuticsCapricor Deramiocel...
82
United States — Food and Drug Administration extended PDUFA date Paragon TherapeuticsCapricor Deramiocel...
82
Paragon Therapeutics extended PDUFA target date United States — Food and Drug AdministrationCapricor Deramiocel...
80
Paragon Therapeutics submitted BLA amendment United States — Food and Drug AdministrationCapricor Deramiocel...
80
Paragon Therapeutics resubmitted Biologics License Application United States — Food and Drug AdministrationCapricor Deramiocel...
78
United States — Food and Drug Administration accepted BLA amendment Paragon TherapeuticsCapricor Deramiocel...
76
Paragon Therapeutics resubmitted Biologics License Application United States — Food and Drug AdministrationCapricor Deramiocel...
71
United States — Food and Drug Administration issued Complete Response Letter Paragon TherapeuticsCapricor Deramiocel...
61
Paragon Therapeutics submitted Biologics License Application United States — Food and Drug AdministrationCapricor Deramiocel...
60
United States — Food and Drug Administration granted review extension Paragon TherapeuticsCapricor Deramiocel...
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and Paragon Therapeutics interact across events, view sentiment trends, and discover connected entities.
Open Dashboard